MED-EL CI System
FDA premarket approval P000025/S129 · decided 2024-10-03
Approval details
- PMA number
- P000025
- Supplement
- S129
- Supplement type
- Panel Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- MED-EL CI System
- Generic name
- Implant, cochlear
- Applicant
- Med-El Corp.
- Date received
- 2023-10-25
- Decision date
- 2024-10-03
- Days to decision
- 344 days
- Decision code
- APPR
- Product code
- MCM
- Advisory committee
- Ear, Nose, Throat
- Expedited review
- No
- Location
- Innsbruck
- Statement
- The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the MED-EL Cochlear Implant (CI) System for expanding the indications for use. The expanded device indications include individuals with bilateral hearing loss who meet the following criteria:The MED-EL Cochlear Implant System is intended to evoke auditory sensations via electrical stimulation of the auditory pathways
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.